Premaitha strikes IONA deal in Greece

Premaitha Health has signed a distribution agreement with a company in Greece to provide its non-invasive prenatal screening test (NIPT), branded IONA, to laboratories in the region.

Premaitha has struck the deal with Antisel SA, a distributor of scientific products in Greece, for the test which detects the risk of a fetus being affected by Down’s Syndrome and other serious genetic conditions such at Patau’s Syndrome and and Edwards Syndrome. The test is carried out by analysing fetal DNA from a sample of maternal blood. As the first and only CE-marked (European approved) test of its kind, the IONA test enables clinical laboratories to run their own in-house service without having to send blood samples to central labs in the USA or China with a wait for results of up to 14 days.

Premaitha chief executive Dr Stephen Little said: “This valuable partnership will enable us to provide the IONA® test to hospitals throughout the country and we look forward to working with the Antisel team to help support clinical teams in setting up their own NIPT screening service.”

See the article in full at TheBusinessDesk.com

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.